These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8646509)

  • 1. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial.
    Wallack MK; Sivanandham M; Whooley B; Ditaranto K; Bartolucci AA
    Ann Surg Oncol; 1996 Mar; 3(2):110-7. PubMed ID: 8646509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
    J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty LE; Richards JM; Bartolucci AA
    Cancer; 1995 Jan; 75(1):34-42. PubMed ID: 7804974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.
    Wallack MK; Sivanandham M; Ditaranto K; Shaw P; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Rosen L; Bartolucci AA
    Ann Surg; 1997 Aug; 226(2):198-206. PubMed ID: 9296514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
    Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials.
    Kim EM; Sivanandham M; Stavropoulos CI; Bartolucci AA; Wallack MK
    Surg Oncol; 2001; 10(1-2):53-9. PubMed ID: 11719029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active specific immunotherapy with vaccinia melanoma oncolysate.
    Wallack MK; Scoggin SD; Sivanandham M
    Mt Sinai J Med; 1992 May; 59(3):227-33. PubMed ID: 1318507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate.
    Wallack MK; Bash JA; Leftheriotis E; Seigler H; Bland K; Wanebo H; Balch C; Bartolucci AA
    Arch Surg; 1987 Dec; 122(12):1460-3. PubMed ID: 3689123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
    Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
    Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
    Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
    J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
    Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
    Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO).
    Wallack MK; McNally K; Michaelides M; Bash J; Bartolucci A; Siegler H; Balch C; Wanebo H
    Am Surg; 1986 Mar; 52(3):148-51. PubMed ID: 3513682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
    Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
    Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
    Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
    Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
    Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
    Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in disease-free survival of melanoma patients in conjunction with serologic response in a phase Ia/Ib Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate.
    Wallack MK; Bash J; Bartolucci A
    Am Surg; 1989 Apr; 55(4):243-7. PubMed ID: 2650593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
    Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
    Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease.
    Voit C; Kron M; Schwürzer-Voit M; Sterry W
    J Dtsch Dermatol Ges; 2003 Feb; 1(2):120-5. PubMed ID: 16285179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates.
    Wallack MK; Michaelides M
    Surgery; 1984 Oct; 96(4):791-800. PubMed ID: 6091287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical activity of a polyvalent melanoma antigen vaccine.
    Bystryn JC
    Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.